cyclophosphamide + doxorubicin + prednisone

This is a combination chemotherapy regimen consisting of three drugs: - **Cyclophosphamide** is an alkylating agent that interferes with DNA replication and RNA transcription, leading to cell death, particularly in rapidly dividing cells. - **Doxorubicin** is an anthracycline antibiotic that intercalates into DNA, inhibits topoisomerase II, and generates free radicals, resulting in cytotoxicity against cancer cells. - **Prednisone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties; it also induces apoptosis in certain cancerous lymphoid cells. This combination may be used as part of multi-agent chemotherapy protocols for the treatment of various hematologic malignancies (such as lymphoma), though it is less common than the standard CHOP regimen (which includes vincristine). The mechanism involves attacking cancer cells through multiple pathways to maximize efficacy and reduce resistance. Each drug has distinct toxicity profiles; combined use requires careful monitoring for side effects such as myelosuppression, cardiotoxicity (from doxorubicin), immunosuppression (from prednisone), and others[4].